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Structural and biochemical alterations of themicrotubule-associated protein tau (MAPT) are associatedwith degenerative disorders
referred to as tauopathies. We have previously shown that MAPT is present in human islets of Langerhans, human insulinomas,
and pancreatic beta-cell line models, with biophysical similarities to the pathological MAPT in the brain. Here, we further studied
MAPT in pancreatic endocrine tissue to better understand the mechanisms that lead to functional dysregulation of pancreatic
beta cells. We found upregulation of MAPT protein expression in human insulinomas when compared to human pancreatic islets
of Langerhans and an imbalance between MAPT isoforms in insulinomas tissue. We cloned one 3-repeat domain MAPT and
transduced this into a beta-cell derived rodent cell line Rin-5F. Proliferation experiments showed higher growth rates andmetabolic
activities of cells overexpressing MAPT protein. We observed that a MAPT overexpressing cell line demonstrates altered insulin
transcription, translation, and insulin secretion rates. We found the relative insulin secretion rates were significantly decreased in
a MAPT overexpressing cell line and these findings could be confirmed using partial MAPT knock-down cell lines. Our findings
support that MAPT may play an important role in insulin granule trafficking and indicate the importance of balanced MAPT
phosphorylation and dephosphorylation for adequate insulin release.
1. Introduction
Pancreatic neuroendocrine cells are located within the islets
of Langerhans and are involved in glucose metabolism in
mammals thereby regulating blood glucose levels. On the
one hand, loss of pancreatic beta cells, which is observed in
diabetes mellitus type 1 and in advanced stages of diabetes
mellitus type 2, leads to decreased insulin production. On
the other hand, uncontrolled proliferation of pancreatic
neuroendocrine cells in pancreatic neuroendocrine tumors
(PanNETs) results in inadequate hormone secretion [1].
PanNETs are rare, accounting for less than 5% of pancreatic
neoplasias yet they represent an important clinical form of
pancreatitis [2].Themost commonPanNETs are insulinomas
with a yearly incidence of 1–4 per 1.000.000 [3]. However,
it was suggested that insulinomas often remain undiagnosed
during life, as their prevalence in autopsy studies reaches up
to 10%. Insulinomas arise in the islets of Langerhans and
usually measure less than 2 cm in diameter. Their increased
insulin production frequently results in hypoglycemia.
Although diabetes and PanNETs represent an opposite
end of the spectrum with respect to blood glucose levels,
the level of secreted insulin is crucial in both conditions.
Therefore, the elucidation of mechanisms and molecules,
which play a role in the control of insulin synthesis and
secretion, is paramount in order to further our understanding
of the pathophysiology of both diabetes and PanNETs.
In the present study, we focus on the microtubule-
associated protein tau (MAPT). Together with MAP2 and
MAP4 [4, 5], MAPT belongs to the family of microtubule-
associated proteins, which stabilize microtubule tracks [6–8].
Microtubules represent the rails for neurotransmitter vesicle
trafficking towards the synapses [9] and for insulin granules
maturation, processing, and prepriming them for exocytosis
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[10–14]. MAPT is present not only in the central nervous
system (CNS) but also in pancreas, breast, prostate, and renal
tubules [15, 16] (http://www.proteinatlas.org/).
Aggregates of abnormally hyperphosphorylated MAPT
are themain constituent of neurofibrillary tangles (NFTs) and
neuropil threads (NTs) that are characteristic neuropatho-
logical hallmark lesions of Alzheimer’s disease (AD) [17, 18].
Interestingly, it has been recently reported that abnormally
hyperphosphorylated MAPT was found in pancreatic islets
of individuals suffering from diabetes mellitus type 2 [19]. In
our previous study, we described the biochemistry of MAPT
in the beta-cell derived rodent cell line Rin-5F [20].
Motivated by these findings, one part of the present
study aimed to evaluate MAPT expression levels in human
pancreatic islets and human insulinomas. In the second part,
we investigated the relevance of MAPT protein for beta cells
using an in vitro pancreatic cell line model.
The process of insulin secretion has been studied in iso-
lated rodent islets [21–23] and beta-cell derived insulinoma
cell lines [24, 25]. Although the coupling between stimulus
and secretion is disrupted in most cell lines [26, 27], the
mode of granule trafficking from immature to preprimed and
primed granules prepared for secretion might be preserved.
The granule maturation process as described for beta cells
[28, 29] and intracellular movement of insulin/transmitter
containing vesicles depends on a functioning microtubular
machinery together with motor proteins and microtubule-
associated proteins such as the MAPT [30].
Overexpression of human MAPT isoforms within neu-
rons has been studied using experimental animalmodels [31–
33].These studies have demonstrated thatMAPT overexpres-
sion leads to axonopathy and has an influence on MAPT
compartmentalization as well as hyperphosphorylation.
Therefore, in the present study, we aimed to investigate
the effects of MAPT overexpression on pancreatic beta-cell
line growth rates and on insulin transcription, translation,
and insulin secretion rates. We also looked at the effects of
knocking down the endogenous MAPT. Our data indicate
the importance of MAPT levels and MAPT phosphorylation
status for pancreatic beta cells’ biology.
2. Material and Methods
2.1. RNA Isolation
2.1.1. Human Islets and Insulinomas Tissue. Total RNA was
isolated from human insulinoma tissues stored frozen after
surgery in liquid nitrogen. Briefly, about 50–100mg of tumor
tissue was homogenized in 1mL TRIzol (Invitrogen, Lofer,
Austria) and total RNA was isolated by phase-separation
and precipitation with isopropanol following the manufac-
turers’ instructions. Human pancreatic islet total RNA was
obtained from the Department of Medical Biochemistry and
Genetics, University of Copenhagen (Denmark) (Professor J.
H. Nielsen). One 𝜇g of total RNA was reverse transcribed
using SuperScript II (Invitrogen) and random primers and
the resultant cDNA was diluted 1 : 3 in H
2
O. Of note, this
part of the study had been approved by the Ethics Committee,
Medical University of Vienna.
2.1.2. Pancreatic Beta-Cell Derived Rodent Cell Line Rin-5F.
Wechoose the rat insulinoma cell line, Rin-5F, a clone derived
from the Rin-m rat islet line (ATTC CRL-2057), as our
main investigative tool for in vitro analysis. This cell line
represents a model to study the biology of pancreatic beta
cells, specifically the mechanism controlling the synthesis,
storage, and secretion of insulin.
Rin-5F cell lines were cultured in complete medium [20]
and harvested into 900 𝜇L TRIzol. The RNA and cDNA were
processed and obtained in the same way as described above.
2.2. RT-qPCR
2.2.1. Human Islets and Insulinomas. In order to measure
all MAPT isoforms in human pancreatic islets and insuli-
nomas, we designed Pan MAPT specific primers: MAPT
fw: (5󸀠-CCTCTCCCGTCCTCGCCTCTG-3󸀠) andMAPT rv:
(5󸀠-GGGTCAGCCATCCTGGTTCA-3󸀠). One 𝜇L of islet or
insulinoma cDNA and five 𝜇L of the SYBR Green/RQX PCR
Master Mix (SA Bioscience, Cat. number PA-012), together
with 10 𝜇M Pan MAPT primers, were used to measure the
relative MAPT gene expression levels. The RT-qPCR was run
on the StepOnePlus PCR machine and calculated using the
ΔΔCT method. Actin was used as a house-keeping gene.
2.2.2. Pancreatic Beta-Cell Derived Rodent Cell Line Rin-
5F. To evaluate individual gene expression levels TaqMan
specific probes from Applied Biosystems (the humanMAPT,
number: Hs00213487 m1 MAPT, Lot.: 471108; the ratMAPT,
number: Rn01495715 m1, Lot.: 612900; the Rat Insulin, num-
ber: Rn02121433 g1 Ins1, Lot.: 771584), together with TaqMan
2xPCRMaster Mix (Applied Biosystems, Lot.: N10545), were
used for RT-qPCR measurements on the StepOnePlus PCR
machine. After normalization of individual samples using
Gapdh (number: Rn01775763 g1 Gapdh, Lot.: 740946) and/or
Pdx1 (number: Rn00755591 m1 Pdx1, Lot.: 455683) as house-
keeping genes, the expression levels were calculated with the
ΔΔCTmethod taking the sham-transfectant or wild type line
as standard.
2.3. PCR for Differentiation 3RD versus 4RD Tau Isoforms.
For differentiating 3-repeat domain (3RD) versus 4-repeat
domain (4RD) MAPT isoforms in human pancreatic islets
and insulinomas, we used the following primers: HE9F2
(5󸀠-ACCCAAGTCGCCGTCTTCCGCC-3󸀠) and HE11R (5󸀠-
CACCTTGCTCAGGTCAACTGGT-3󸀠) specific for exons 9
and 11, respectively [34]. This revealed PCR products of
170 bp when excluding exon 10 (E10−, which corresponds
to 3RD MAPT isoforms) and 256 bp when including exon
10 (E10+, which corresponds to 4RD MAPT isoforms). The
PCR conditions were 35 cycles: 95∘C, 68∘C, and 72∘C with
7min extension at the end, using high fidelity polymerase
(Roche, Basel, Switzerland). In order to measure the product
within the linear amplification phase, the PCR reaction was
terminated between cycles 27 and 29. Product separation
was carried out at a 1.5% agarose gel and band intensity
was quantitated using Lumi Imager F1 (Roche) and Image J
program.
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2.4. Cloning of Human Tau Isoforms. Human cDNA (as
template) together with the forward primer 5󸀠-ATGGCT-
GAGCCCCGCCAG-3󸀠 and reverse primer 5󸀠-TCACAA-
ACCCTGCTTGGCCA-3󸀠 was used for amplification of the
coding region of human MAPT. PCR conditions were 35
cycles: 95∘C for denaturing, 62.5∘C for annealing, and 72∘C
for synthesis with 7min extension at the end, using high
fidelity polymerase (Roche). The resultant PCR product was
analysed at a 1% agarose gel, the MAPT specific bands
were cut out, and the DNA amplicons were bound to glass
beads (at RT, o/n under constant rotation) (S&S Elu-Quik,
Schleicher & Schuell, Germany). After washing, glass beads
were vacuum dried and DNA was eluted into 50 𝜇L H
2
O
(2min at 50∘C).
The DNA fragments (3 𝜇L) were ligated into the pGEM-
T Easy vector system following manufacturer’s instructions
(Promega, Madison, WI, USA). The ligation product (2𝜇L)
was transformed into One Shot TOP10 Chemically Compe-
tent E. coli (Invitrogen) with heat-shock method following
manufacturer’s instruction and grown on LB/Amp/X-gal
plates (o/n at 37∘C). White colonies were inoculated into
TY/Ampmedium, grown for 16 h at 37∘C, and plasmids were
isolated by the miniprep method (Qiagen) and the inserts
were identified by restriction enzymes digest (EcoR I) and
sequencing.
For engineering of the protein expression vector, a novel
forward primer including CACC at the 5󸀠 end was designed,
and the 3RD-MAPT3 isoform encoding pGEM-T Easy plas-
mid was chosen as template. The resultant PCR product
was cloned into the pENTR/D-TOPO vector as indicated
in the manufacturer’s test manual (Life Technologies). The
recombinant vector was transformed into One Shot TOP10
Chemically Competent E. coli (Invitrogen) and grown o/n on
LB/Kanamycin plates. Outgrowing colonies were inoculated
in TY/Kanamycin medium, grown for 16 h; plasmids were
isolated by the miniprep method (Qiagen) and inserts were
identified by restriction enzymes using Hind III and Not
I. The resultant entry clone was used for transferring the
insert into the expression/destination vector: pEXP1-DEST
(Invitrogen).The LR clonase reaction was carried out at 25∘C
as indicated in the testmanual (in brief: 2𝜇LLR clonase IIwas
mixed with 150 ng Tau pENTR/D-TOPO plasmid and 150 ng
wild type pEXP1-DEST vector in a total volume of 10 𝜇L) and
transformed into chemically competent cells using the heat-
shock method as indicated above. Outgrowing colonies were
inoculated in TY medium, grown for 16 h at 37∘C; insert-
containing plasmid was verified (by restriction enzyme digest
Hind III), transformed into BL21 codon plus bacteria, and
cloned on TY/Amp plates. A single colony was inoculated
into an Erlenmeyer flask in 25mL TY/Amp medium o/n.
For induction of protein expression, the IPTG (100 𝜇M) was
added (6 hr incubation at 31∘C under constant rotation). The
bacterial culture was harvested by centrifugation at 3200 rpm
for 12min and the resultant pellet was lysed in 4M Urea,
100mM phosphate, and pH 8 lysis buffer. The cell debris
was separated by centrifugation at 10000 rpm on a J2-MC
centrifuge (Beckman) at 4∘C and the obtained supernatant
was incubated (1 hr at 4∘C under constant rotation) with
the Ni-NTA His-Bind Resin preequilibrated in lysis buffer.
Loaded beads were washed three times using 1x Ni-NTA
washing buffer (300mM NaCl, 50mM sodium phosphate
buffer, 20mM imidazole, and pH 8.0). MAPT protein was
eluted using 1xNi-NTA elution buffer (300mMNaCl, 50mM
sodium phosphate buffer, 250mM imidazole, and pH 8.0).
Eluted fractions were tested for protein content and size by
SDS-PAGE and Coomassie Blue staining.
For generating a mammalian expression plasmid, the
clonase reaction was performed using pENTR/D-TOPO
MAPTencoding plasmid togetherwith pMSCVempty vector
similarly as described above. Briefly, 150 ng pENTR/D-TOPO
MAPT was combined with 150 ng pMSCV empty vector in
6 𝜇L TE buffer including 2𝜇L clonase II in a final volume of
10 𝜇L. The clonase reaction was transformed into One Shot
TOP10 chemically competent E. coli (Invitrogen). Clones
were selected on TY/Amp plates and grown out in TY
medium (16 h at 37∘C) and the pMSCV Tau plasmid was
purified using Qiagen columns.
2.5. Generation of MAPT Encoding Retroviral Particles. Re-
combinant retroviruses were produced by transient trans-
fection using HEK-293FT cells (Invitrogen). HEK-293FT
cells were transfected with retroviral vector pMSCV MAPT
(3RD-MAPT3) and plasmids encoding GAG-POL and VSV-
G using lipofectamine 2000 (Invitrogen), according to the
recommendation of the manufacturer.
The Rin-5F cells were used for the retroviral-mediated
overexpression of MAPT. Semiconfluent Rin-5F cells were
retrovirally transduced by spin infection (800×g, 90min,
32∘C) in the presence of polybrene (7 𝜇g/mL). Four days after
transduction, cells were treated with puromycin (1 𝜇g/mL)
for chemoselection. The culture supernatant was exchanged
every third day and outgrowing cells were passaged every
fourth day.
Sham-transfectant Rin-5F cells were obtained by trans-
ducing Rin-5F cells using empty pMSCV vector and chemos-
electing for resistant cells with puromycin (1 𝜇g/mL).This cell
line was used for comparative reason and is named later an
Empty cell line.
2.6. Tau Knockdown. For RNA interference experiments,
the siRNA encoding lentivirus compatible plasmids were
purchased from Thermo Scientific (Cat. number: RHS4533,
Clone numbers: TRCN0000083973, TRCN0000083974,
TRCN0000083975, and TRCN0000083976). The four
plasmids were separately amplified in E. coli and used for
generation of siRNA encoding virus particles. Recombinant
lentiviruses were produced as described previously [35].
The wild type Rin-5F cell line was transduced with each
of the Mapt siRNAs as described above. Individual cell lines
were grown out following chemoselection with puromycin
(1 𝜇g/mL).
2.7. Immunofluorescence. Cytospin preparations of MAPT
overexpressing and Empty cell lines were fixed in acetone
for 5min, blocked with RPMI 1640 medium containing
10% FCS for 10min, and subsequently stained with the
polyclonal rabbit anti-human Tau Ab (Cat. number A 0024,
DakoCytomation, Denmark) (diluted 1 : 200 in PBS) over
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night at 4∘C. Following washing in 0.05% (v/v) Tween-PBS
for 15min, a secondary Ab was applied, the goat anti-rabbit
Alexa 488 (Cat. number P0448, DakoCytomation) (diluted
1 : 200 in PBS), and incubated for 2 h at RT. The slides were
mounted with Vectashield (Vector Laboratories, Burlingame,
CA, USA). Images were taken using the Axiovert confocal
microscope 200M (Zeiss Jena, Germany) and processed
using LSM 5 software (Zeiss).
2.8. Immunoblotting. The Western blotting was essentially
performed as described in [20]. In brief, 2 × 106 Rn-5F cells
(Empty and MAPT overexpressing cell lines: not treated or
treated for 1 h with either 1 𝜇M or 1 nM Wortmannin or
with dimethyl sulfoxide (DMSO) as a control) were lysed
individually in 100 𝜇L Weinberg buffer (50mM Hepes, pH
7.0, 0.5% Nonidet P-40, 250mM NaCl, and 5mM EDTA)
containing phenylmethylsulfonyl fluoride (10mM), sodium
vanadate (10mM), and 𝛽-glycerophosphate (1M). After pre-
clearing cell lysate by centrifugation at 13000 rpm for 10min,
the supernatant was combined with SDS sample buffer
and loaded onto 10% SDS-PAGE, which was then blotted
onto Immobilon-P Transfer Membrane (Millipore, Vienna,
Austria) using a semidry blotting device. Blockedmembranes
were exposed o/n at 4∘C to primary antibodies: polyclonal
rabbit anti-humanTau (dilution 1 : 5000, Cat. numberA0024,
DakoCytomation, Denmark, Glostrup), anti-human PHF-
TaumAb, clone AT8 (dilution 1 : 2500, Lot. number FK 93121,
Pierce, Rockford, IL, USA), and mouse monoclonal anti-
𝛽-actin (dilution 1 : 5000, Cat. number NB600-501, Novus
Biologicals, Littleton, CO, USA). Following washing in TPBS,
the HRP-conjugated goat-anti rabbit (DakoCytomation, Cat.
number P0048) or goat-anti mouse (DakoCytomation, Cat.
number P0047) was applied and sites of antibody binding
were visualized by chemiluminescence which was recorded
by Lumi Imager F1 (Roche).
2.9. MTT Assay. Equal numbers (2 × 105) of Empty and
MAPT overexpressing Rin-5F cell lines were seeded in
quadruplicates onto a 24-multiwell plate and incubated with
1mL complete medium for 36 h and 60 h. After the respec-
tive incubation period, the culture medium was replaced
with RPMI containing MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) (500 𝜇g/mL). Following
60min incubation, the medium containing MTT was
removed and the resultant formazan dye was dissolved in
HCl acidified (50mM) DMSO containing SDS (10% w/v).
The colour intensity was evaluated by spectrophotometric
measurement (𝜆 = 562 nm).
2.10. Cell Proliferation by Evaluation of Cell Number. Equal
numbers of Empty and MAPT overexpressing cells were
plated onto culture dishes, and the cell number was evaluated
by a cell counter (XE-2100 Sysmex) after 60 h.The experiment
was carried out three times at different time points in
triplicate.
2.11. Insulin Secretion Assay. (a) Empty and MAPT overex-
pressing Rin-5F cell lines (2 × 105 cells/well) were seeded
into 250𝜇L RPMI 1640 culture medium and stimulated with
20mM KCl (final concentration). After 2 h incubation, the
supernatant was harvested and centrifuged at 1000×g for
5min to pellet cells. Nonstimulated cells were included as
a control. For measuring intracellular insulin content, cells
were lysed using 1% (v/v) Tween-PBS.
(b) Empty and MAPT overexpressing Rin-5F cell lines (4
× 105 cells/well) were seeded onto 12-well plate. After 24 h cul-
turing to obtain cell adherence, the culture supernatant was
changed by either only prewarmed RPMI 1640 or prewarmed
RPMI 1640 supplemented with the Wortmannin (1 𝜇M).
Following an incubation period of 2 h at 37∘C, an aliquot
of 200𝜇L was harvested and kept at 4∘C until measurement
of insulin level. Further aliquots (in quadruplicates) were
harvested at 4, 6, 10, and 24 h incubation period.
Each experiment was carried out in triplicate at three
different days.
An Insulin RIA (Radioimmunoassay). An Insulin RIA (Radio-
immunoassay) (Cat. number RI-13K, Millipore, Billerica,
MA, USA) was used to determine insulin content of individ-
ual samples.The assay is based on the radioactive 125I-labeled
insulin and it utilizes a Rat Insulin antiserum. The assay
was performed as described in the assays’ manual. In brief,
standards, quality controls, and samples diluted with assay
buffer, 1 : 10 (samples harvested at 1, 2, 3, and 4 h incubation),
1 : 20 (at 6 h), and 1 : 50 (at 24 h), were incubated over night
at 4∘C with 125I-Insulin Tracer and Rat Insulin Ab. On the
following day, the precipitating reagent was added. After an
incubation period of 20min, the supernatant was decanted
and dried tubes were measured in a gamma counter for 1min
each.
3. Results
3.1. MAPT Expression in Islets and Insulinomas. MAPT is
highly expressed in the central nervous system (CNS) where
it plays a crucial role in the axonal transport and neurite out-
growth [8, 36, 37]. However, MAPT was shown to be present
also in other tissues [15, 16, 38] (http://www.proteinatlas.org/)
like the endocrine parts of the pancreas, breast, prostate, and
renal tubules.
Following our previous findings that MAPT is highly
expressed in pancreatic islets of Langerhans [20], we raised
the question whether MAPT is expressed at the same level in
the islets of Langerhans isolated from healthy organ donors
versus pancreatic insulinoma tumors. For that reason, we
analyzedRNA from islets of healthy organ donors (𝑛 = 3) and
from insulinomas (𝑛 = 5) for reverse transcription. Obtained
cDNA was used to check the MAPT gene expression level.
Interestingly, MAPT expression is over 3 times higher in
insulinomas when compared to islets, SD ± 0.12 (𝑝 < 0.01)
(Figure 1).
3.2. MAPT Isoforms. The distortion of normal equimo-
lar ratio between 3-repeat domain (3RD) and 4-repeat
domain (4RD) MAPT isoforms is observed in human brain
tauopathies. Following this, we used predesigned specific
primers that recognize MAPT isoforms containing exon 10
(HE11R) and missing exon 10 (HE9F2) and subsequently
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Figure 1: RT-qPCR of RNA isolated from human islets and human
insulinomas. Expression of MAPT gene level evaluated in human
islets (𝑛 = 3) and in human pancreatic insulinomas (𝑛 = 5); 𝑝 <
0.01.
performedPCR.Thismethodhas been previously shown [34]
to provide different size fragments depending on whether
exon 10 is out-spliced or keptwithin themRNA.The fragment
size is 170 bp for E10− and 265 bp for E10+. A balanced ratio
= 1, SD ± 0.07 isoform expression (3RD to 4RD) was found
in islets (𝑛 = 4), whereas an inverse ratio = 1.2, SD ± 0.18 was
found in insulinoma tissue (𝑛 = 7), 𝑝 < 0.05.
3.3. Frequency Appearance of Specific MAPT Isoforms. The
six MAPT isoforms (MAPT1 to MAPT6) expression is
well documented in the human brain [39, 40]. Therefore,
we investigated whether the same isoforms can be found
in human beta-cell tumors. For this reason, we separated
insulinoma tumor and cerebellum proteins in an SDS-PAGE
gel and performed pan MAPT specific immunoblotting. As
shown in Figure 2(a), two distinct isoformswere the predom-
inant isoforms in insulinoma. To further characterize these
isoforms we reverse-transcribed insulinoma tumor RNA and
subcloned the PCR amplified cDNA into the pGEM-T Easy
replication plasmids. The inserts were sequenced and were
shown to contain exclusively the coding region of MAPT3
(corresponding to MAPT3 protein: 381aa long isoform)
or MAPT4 (corresponding to MAPT4 protein: 412aa long
isoform) (Figure 2(b)).
3.4. Transgene Overexpression and Characterization of Cell
Lines. The microtubular machinery (a part of which is
MAPT) together with motor proteins plays a crucial role
in the insulin/transmitter containing vesicles intracellular
trafficking and their expulsion. To follow this, we transduced
an insulinoma cell line with the 3-repeat domain MAPT,
namely, MAPT3 (381aa) isoform, to test its effect on insulin
secretion.
Using human cDNA as template, we amplified MAPT
encoding isoforms and cloned one of them into an E.
coli expression plasmid. Employing E. coli BL21 we gen-
erated a His-tagged MAPT protein. The purified MAPT
protein has been used to visualize its size of expression
with our Abs. Following the successful attempt of bacterial
expression (Figure 3(a)), we transferred the coding sequence
of MAPT isoform 3RD-MAPT3 into a retrovirus-based
mammalian expression plasmid as described in Section 2.
After packaging the expression plasmid into a lentiviral
particle, the Rin-5F insulinoma cell line was transduced and
subsequently selected for MAPT gene overexpressing cells
using puromycin. The outgrowing cell line was expanded
and tested for MAPT protein overexpression (Figure 3(b)).
Western blotting allowed the detection of a 10-fold stable
overexpression of MAPT in the transgenic cell line when
compared to the Empty cell line.
3.5. Immunofluorescence. In order to establish the morphol-
ogy and intracellular topology of the transduced versus
Empty cell line confocal microscopy images were taken.
Higher cytoplasmic MAPT protein staining within the
MAPT overexpressing cell line but with the absence of any
aggregates or tangle formation was observed. Interestingly,
not 100% of the cell population showed this high level of
MAPT staining, but this seemed to depend on the stage of
the cell cycle (Figure 4).
3.6. Cell Replication. Already when establishing both cell
lines it came into our attention that a higher growth rate
might be specific to the transgene expressing cell line. This
observation could be ascertained by assessing proliferation
rate by cell counting. MAPT overexpression in this cell line
significantly accelerates (𝑝 < 0.05) cell growth by about 25%
(Figure 5(a)).
In addition, the colorimetric MTT assay was determined
which demonstrated about 60% higher activity rate of the
MAPT overexpressing cell line when compared with Empty
cell line (𝑝 < 0.05) (Figure 5(b)).
3.7. Influence of MAPT Overexpression on Gene Expression.
It was previously shown that MAPT binds to DNA and
thus it most probably affects chromatin [41, 42]. To evaluate
the influence of MAPT overexpression on insulin gene
expression, we performed RT-qPCR with both cell lines and
observed about twofold higher levels of Ins1 gene transcrip-
tion in the MAPT overexpressing cell line (𝑛 = 4) (SD ± 0.15)
compared to Empty (𝑛 = 4) (SD± 0.09) (𝑝 < 0.05) (Figure 6).
3.8. Influence on Insulin Secretion Processes. MAPT has an
influence on microtubule stabilization.The tubular transport
of secretory granules is a key player in endocrine secretory
processes.Therefore, measurement of insulin secretion of the
transduced cell lines was examined.
At first, we determined the total insulin content, and the
results confirmed the RNA data: the total insulin content
was much higher in MAPT overexpressing cells (52.6 ± SD
4.18 ng/2 × 105 cells) than in Empty (24.5 ± SD 2.68 ng/2 ×
105 cells), 𝑝 < 0.05.
Interestingly, when the insulin release from MAPT over-
expressing versus Empty cell lines was measured upon
stimulation with 20mM KCl, the MAPT overexpressing
cells showed significantly lower insulin secretion rates
(Figure 7(a)) when calculated in the percentage of the total
intracellular insulin content.This lower percentage of insulin
release in MAPT overexpressing cells was not only observed
under stimulated conditions, but it was also observed under
normal culture conditions.
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Figure 2: MAPT protein appearance at insulinoma tissue. (a) Comparison of MAPT protein electrophoretic pattern (10% SDS-PAGE gel)
from cerebellum and human insulinoma tissue. (b) Subcloned insulinoma tumor cDNA into the pGEM-T Easy replication plasmids. Lower
bands demonstrate inserts which contained exclusively the coding region of MAPT3 or MAPT4.
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Figure 3: (a) Bacterial expression of MAPT isoform (3RD-MAPT3, 381aa). Ni-NTA purified human recombinant His-tagged MAPT
visualized by Coomassie Blue staining (upper panel).The immunoblotting of recombinantly producedMAPT in BL21 E. coli visualized by the
panMAPT specific Ab (lower panel). (b) Overexpression of 3RD-MAPT3 in Rin-5F cells.The immunoblotting ofMAPT overexpressing Rin-
5F cell line versus Empty Rin-5F cell line using a pan MAPT specific Ab. Densitometric measurements showed 10-fold stable overexpression
of MAPT in the transgenic cell line.
Graph represents a mean of three independent experi-
ments ±SD.
3.9. Wortmannin Treatment. In order to assess whether
MAPT phosphorylation dynamics is important for antero-
grade transport and thereby for insulin trafficking, we
included the phosphatidylinositol 3-kinase (PI3K) inhibitor,
Wortmannin [43]. Inhibition of PI3K leads to the over-
activation of glycogen synthase kinase 3𝛽 (GSK-3𝛽) and
consequently to MAPT hyperphosphorylation. Application
of Wortmannin causes strong MAPT hyperphosphorylation
in both Rin-5F cell lines (data not shown).
Interestingly, one 𝜇MWortmannin reduced significantly
the insulin secretion rates in both treated cell lines, 𝑝 <
0.05 (Figure 7(b)). The insulin secretion rates were evalu-
ated in ± Wortmannin treated MAPT overexpressing and
Empty cell lines during the period of 24 h. This data could
reflect the importance of balanced MAPT phosphorylation-
dephosphorylation status. Graph represents the mean of
three independent experiments ±SD.
3.10. MAPT Knockdown. To further investigate the role of
MAPT in insulin trafficking, we aimed to knock down
endogenousMapt gene in the Rin-5F insulinoma cell line. For
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Figure 4: Confocal immunofluorescence staining of Rin-5F cell lines. MAPT overexpressing cell line (a) and Empty (b) stained by the pan
MAPT specific Ab followed by Alexa Fluor goat anti-rabbit Ab. Images were taken by Axiovert confocal microscope 200M (Zeiss Jena,
Germany).
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Figure 5: (a) Cell proliferation. Growth rate of MAPT overexpressing cell line versus Empty; 𝑝 < 0.05. Presented data are means from three
independent experiments ± SD. (b) MTT colorimetric assay (over a time period of 60 h) comparing MAPT overexpressing Rin-5F cell line
versus Empty; 𝑝 < 0.05. Presented data are means calculated from three independent experiments ± SD.
that reason, we transduced 4 differentMapt small interfering
RNAs (siRNAs) encoding plasmids separately by means of
lentiviral approach into the Rin-5F insulinoma cell line.
However, these transduced cell lines had a slow division rate
and higher apoptotic rate than wild type cells. Nevertheless,
we evaluated the silencing efficiency at the mRNA level by
RT-qPCR (Figure 8) reaching up to 60%ofMapt knockdown.
Furthermore, we examined if partly silencedMapt influences
insulin expression (Figure 8): in three out of four cell lines,
the insulin gene expression level was significantly reduced
(up to 60%) going in line with the Mapt gene knock-down
effects.
Consequently, we assessed protein expression level by
Western blotting.This confirmed reduction ofMAPT protein
expression (data not shown).
4. Discussion
In the present study, we examined MAPT, which represents
one of themost importantmolecules formicrotubule dynam-
ics and trafficking within the cell. We demonstrated MAPT
expression in human pancreatic islets of Langerhans and its
upregulation in human insulinomas. Moreover, we studied
its relevance in pancreatic islets using the beta-cell derived
8 Journal of Diabetes Research
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Figure 6: RT-qPCR of RNA isolated from Rin-5F. Ins1 gene
expression in MAPT overexpressing (𝑛 = 4) versus Empty cell line
(𝑛 = 4) was evaluated using the ΔΔCT method; 𝑝 < 0.05.
rodent Rin-5F cell line transduced with one of the MAPT
isoforms (3-repeat domain MAPT, namely, MAPT3). Our
data suggest an influence of MAPT on insulin transcription,
secretion, and growth dynamics of the Rin-5F cell line.
MAPT plays an important role in microtubule stabiliza-
tion and neurite outgrowth in the CNS [8, 36, 37, 44]. If
MAPT is abnormally hyperphosphorylated it cannot exert its
function, and this loss of function ultimately leads to neu-
ronal pathology including disintegration of axonal tubulin
[45–47]. Neuropathologically, these changes are present as
intracytoplasmic NFTs and as NTs in axons and dendrites;
NFTs and NTs are hallmark lesions of AD and may also
be seen in other tauopathies [48–50]. In line with the
notion of MAPT expression in non-CNS tissue including
the pancreas [16, 38], an analogy between AD and type 2
diabetes mellitus (T2DM) has been suggested [51–54], in
particular with respect to insulin signaling pathway dys-
function, protein aggregation, and oxidative events. We have
previously demonstrated MAPT expression in a pancreatic
beta-cell line model, human pancreatic islets of Langerhans,
and human insulinomas [20] and described biochemical
features of pancreaticMAPT that are somewhat similar to the
hyperphosphorylated MAPT in AD brains.
In the present study, we further characterized pancreatic
MAPT to better understand the mechanisms leading to
dysregulation in pancreatic endocrine cells. At first, we
evaluated the MAPT expression profile in the human islets
of Langerhans from healthy organ donors and from human
insulinomas. We found that MAPT3 (381 amino acids) and
MAPT4 (412 amino acids) isoforms occur at much higher
frequency than other MAPT splice variants which we have
demonstrated at themRNAand the protein level. Our finding
of 3 times higherMAPTexpression in pancreatic insulinomas
compared to healthy islets suggests that MAPT might be
involved in insulinoma tumor biology.
It has been shown that, in respect to the microtubule
binding domain, MAPT occurs in two splice variants
containing either 3- (3RD) or 4- (4RD) repeat domain.
Tauopathies in the CNS are characterized by the presence
of either 3RD MAPT (e.g., Pick’s disease) or 4RD MAPT
(e.g., progressive supranuclear palsy) or both in imbalanced
ratio (e.g., AD) [54–59]. Strikingly, we found an imbalance
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Figure 7: Insulin secretion. (a) Insulin secretion after stimulation
for 2 h with 20mMKCl. Insulin secretion fromMAPT overexpress-
ing cells versus Empty was calculated in the percentage of total
intracellular insulin content; 𝑝 < 0.05. (b) MAPT overexpressing
Rin-5F cell line versus Empty over a time period of 24 hours.
Cell lines were either grown in RMPI 1640 medium or in RMPI
1640 medium supplemented with 1𝜇MWortmannin. Each column
representing relative insulin secretion level is obtained for respective
cell line as described in the legend attached directly to the graph.The
insulin secretion was normalized to the total intracellular insulin
content. Data is presented from 3 independent experiments ± SD.
in human insulinomas (ratio 3RD : 4RD >1), whereas no
disproportion was found in human islets. These findings
suggest that the imbalance between 3RD and 4RD MAPT
isoforms might be of clinical relevance in insulinomas.
In order to find further proof for this hypothesis, we
studied MAPT in a beta-cell derived rodent insulinoma Rin-
5F cell line, which represents a model for the evaluation of
mechanisms controlling transcription, storage, and secretion
of insulin.
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Figure 8: MAPT knockdown. RT-qPCR of RNA isolated from
three different MAPT siRNA transduced Rin-5F cell lines (marked
as numbers 1, 2, and 3). The rat endogenous Mapt and Ins1 gene
expression level was evaluated using the ΔΔCT method.
Therefore, we cloned one of the MAPT isoforms; we have
chosen the shorter isoform 3RD MAPT (381aa, named also
MAPT3) as this occurred in human insulinomas in higher
copy number than 4RD. After successful generation of a
stable MAPT overexpressing Rin-5F cell line, we studied the
potential influence of MAPT on cell growth and on insulin
transcription and secretion.
We found higher cell replicative potential at the MAPT
overexpressing cell line which was reflected in much higher
MTT activity. Interestingly, the proliferation data could
reflect the human clinical data: high MAPT expression level
in human insulinomas is going in line with an elevated
growth rate of tumor tissue. Noteworthy, the Rin-5F cell
lines transduced with plasmids encoding MAPT siRNAs had
higher apoptotic rates than wild type Rin-5F and also much
slower growth rate. Our findings at the in vitro pancreatic
beta-cell models support the suggestion thatMAPT has some
influence on the biology of these cell lines, especially on theirs
growth dynamics.
Furthermore, as it was previously demonstrated in vitro
and in vivo that MAPT interacts with DNA [42], we hypoth-
esized that MAPT overexpression could cause alterations
at nuclear level in Rin-5F cells. Indeed, the RNA analysis
confirms that the MAPT overexpressing cell line has about
2 times higher expression of the insulin gene. Moreover, the
insulin protein level confirmed the mRNA data as the MAPT
overexpressing cell line displayed about twice as high insulin
content when compared to Empty.
Since MAPT is a major player in the microtubule trans-
port machinery, and as the tubular transport of secretory
granules is fundamental for endocrine secretion, we eval-
uated insulin release. According to our data, the relative
amount of secreted insulin from the MAPT overexpressing
cell line is lower when taken as a percentage of total intra-
cellular insulin. Our finding is in line with earlier studies
on nonneuronal cell types overexpressing MAPT where they
have shown that this protein inhibits anterograde organelle
transport [60, 61]. Ebneth suggested that MAPT by binding
to microtubules slows down intracellular transport [60].
Interestingly, the upregulation of glycogen synthase
kinase 3𝛽 (GSK3𝛽), a main kinase influencing MAPT phos-
phorylation status, results in MAPT hyperphosphorylation
and, subsequently, the distortion of the anterograde transport
[62].
In this respect, the continuous phosphorylation and
dephosphorylation of MAPT protein are crucial for its
biological function. Hence, we intended to influence the con-
tinuous phosphorylation and dephosphorylation of MAPT
protein by applying Wortmannin. Interestingly, we saw a
marked reduction in insulin secretion under time dependent
Wortmannin application. We suspect that hyperphosphory-
lated MAPT cannot bind to microtubules and stabilize them;
therefore, insulin granules trafficking is disturbed. Our data
support the hypothesis that a balance between the levels of
GSK3𝛽 and MAPT phosphorylation is required to maintain
anterograde transport.
In further studies on this subject it might be of interest
to investigate the posttranslational modifications, especially
phosphorylation and glycosylation ofMAPT in various forms
of diseases in which insulin secretion is changed. This
concerns neuroendocrine cells by T2DM, insulinoma, and
Alzheimer’s disease.
To gain further insight into the importance of MAPT
in insulin trafficking, we attempted to knock down MAPT
by means of siRNAi. Successful knocking down MAPT at
the gene level was followed by marked reduction in insulin
gene transcription. Of note, we encountered problems with
growing the MAPT siRNA transduced cell lines and did not
perform insulin secretion assays, as the cell number was
limited due to high apoptosis rates. We think that a secretion
assay under such unfavorable conditions is unreliable.
Taken together, our data strongly indicate the importance
of MAPT for the pancreatic beta-cell. On the one hand,
MAPT might have an influence on a pancreatic tumor
formation and its outgrowth. Not only the elevated level
of MAPT transcription rates in tumor tissue, but also a
disproportion between 3RD and 4RDMAPT isoforms might
have an impact on pathological changes. On the other hand,
MAPT might influence the anterograde transport and thus
the insulin trafficking from the beta cells.
However, further studies are warranted to identify in
more detail the role of MAPT in insulin exocytosis.
5. Conclusions
In this study, we demonstrate significant upregulation of
MAPT gene and protein expression in human insulinoma
tumor tissues when compared to healthy islets of Langerhans.
Our data support the hypothesis that MAPT may be one of
the key players contributing to growth dynamics of beta-cell
derived rodent Rin-5F cell line. Furthermore, we find that
MAPT influences insulin gene transcription rate and might
be an important protein in insulin trafficking. We conclude
that the disturbed phosphorylation and dephosphorylation
10 Journal of Diabetes Research
status of MAPT contribute to the deregulation of insulin
secretion.
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